TSS, INC. Reports Third Quarter Revenue of $70.1 Million, Up 689%

Stock Information for Oncotelic Therapeutics Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Oncotelic Therapeutics Inc

OTC Markets Group Announces Quarterly Index Performance and Rebalancing
TSS, Inc. Announces New $20M Debt Financing to Meet Accelerating Demand for AI-Enabled Technologies
TSS, Inc. Signs Long Term Lease for Larger Factory to Support Accelerating Demand for AI-Enabled Technologies
TSS, Inc. Announces Uplisting to The Nasdaq Capital Market
TSS, Inc. to Attend the 15th Annual Craig-Hallum Alpha Select Conference
TSS, Inc. to Report Third Quarter 2024 Results on Thursday, November 14, 2024
TSS, Inc, Relocating and Expanding Factory to Address Accelerating Demand for AI-Enabled Technologies
TSS, Inc. to Present at LD Micro Main Event XVII

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.